This site is intended for U.S. healthcare professionals.
RETACRIT is indicated for the treatment of anemia due to CKD, including patients on dialysis and not on dialysis, to decrease the need for red blood cell (RBC) transfusion.
RETACRIT is indicated for the treatment of anemia due to zidovudine administered at ≤4,200 mg/week in patients with HIV infection with endogenous serum erythropoietin levels of ≤500 mUnits/mL.
RETACRIT is indicated for the treatment of anemia in patients with nonmyeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of 2 additional months of planned chemotherapy.
RETACRIT is indicated to reduce the need for allogeneic RBC transfusions among patients with perioperative hemoglobin >10 to ≤13 g/dL who are at high risk for perioperative blood loss from elective, noncardiac, nonvascular surgery. RETACRIT is not indicated for patients who are willing to donate autologous blood preoperatively.
See next section for Limitations of Use.
RETACRIT has not been shown to improve quality of life, fatigue, or patient well-being.
RETACRIT is not indicated for use:
Studies in support of biosimilarity
Studies in support of biosimilarity
References:
WARNINGS: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE
CHRONIC KIDNEY DISEASE
CANCER
PERISURGERY
CONTRAINDICATIONS
RETACRIT® is contraindicated in patients with:
RETACRIT® from multiple-dose vials contains benzyl alcohol and is contraindicated in:
INCREASED MORTALITY, MYOCARDIAL INFARCTION, STROKE, AND THROMBOEMBOLISM
INCREASED MORTALITY AND/OR INCREASED RISK OF TUMOR PROGRESSION OR RECURRENCE IN PATIENTS WITH CANCER
HYPERTENSION
SEIZURES
LACK OR LOSS OF HEMOGLOBIN RESPONSE TO RETACRIT®
PURE RED CELL APLASIA
SERIOUS ALLERGIC REACTIONS
SEVERE CUTANEOUS REACTIONS
RISK OF SERIOUS ADVERSE REACTIONS DUE TO BENZYL ALCOHOL PRESERVATIVE
RISK IN PATIENTS WITH PHENYLKETONURIA
DIALYSIS MANAGEMENT
ANEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE
ANEMIA DUE TO CHEMOTHERAPY IN PATIENTS WITH CANCER
SURGERY/PERISURGERY
ANEMIA DUE TO ZIDOVUDINE IN PATIENTS WITH HIV INFECTION
ANEMIA DUE TO CHRONIC KIDNEY DISEASE
RETACRIT® is indicated for the treatment of anemia due to CKD, including patients on dialysis and not on dialysis, to decrease the need for RBC transfusion.
ANEMIA DUE TO ZIDOVUDINE IN PATIENTS WITH HIV INFECTION
RETACRIT® is indicated for the treatment of anemia due to zidovudine administered at ≤4,200 mg/week in patients with HIV infection with endogenous serum erythropoietin levels of ≤500 mUnits/mL.
ANEMIA DUE TO CHEMOTHERAPY IN PATIENTS WITH CANCER
RETACRIT® is indicated for the treatment of anemia in patients with nonmyeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy.
REDUCTION OF ALLOGENEIC RED BLOOD CELL TRANSFUSIONS IN PATIENTS UNDERGOING ELECTIVE, NONCARDIAC, NONVASCULAR SURGERY
RETACRIT® is indicated to reduce the need for allogeneic RBC transfusions among patients with perioperative hemoglobin >10 to ≤13 g/dL who are at high risk for perioperative blood loss from elective, noncardiac, nonvascular surgery. RETACRIT® is not indicated for patients who are willing to donate autologous blood preoperatively.
Limitations of Use
RETACRIT® has not been shown to improve quality of life, fatigue, or patient well-being.
RETACRIT® is not indicated for use:
Please see full Prescribing Information, including BOXED WARNINGS and Medication Guide, for RETACRIT.
ANEMIA DUE TO CHRONIC KIDNEY DISEASE
RETACRIT® is indicated for the treatment of anemia due to CKD, including patients on dialysis and not on dialysis, to decrease the need for RBC transfusion.
ANEMIA DUE TO ZIDOVUDINE IN PATIENTS WITH HIV INFECTION
RETACRIT® is indicated for the treatment of anemia due to zidovudine administered at ≤4,200 mg/week in patients with HIV infection with endogenous serum erythropoietin levels of ≤500 mUnits/mL.
ANEMIA DUE TO CHEMOTHERAPY IN PATIENTS WITH CANCER
RETACRIT® is indicated for the treatment of anemia in patients with nonmyeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy.
REDUCTION OF ALLOGENEIC RED BLOOD CELL TRANSFUSIONS IN PATIENTS UNDERGOING ELECTIVE, NONCARDIAC, NONVASCULAR SURGERY
RETACRIT® is indicated to reduce the need for allogeneic RBC transfusions among patients with perioperative hemoglobin >10 to ≤13 g/dL who are at high risk for perioperative blood loss from elective, noncardiac, nonvascular surgery. RETACRIT® is not indicated for patients who are willing to donate autologous blood preoperatively.
Limitations of Use
RETACRIT® has not been shown to improve quality of life, fatigue, or patient well-being.
RETACRIT® is not indicated for use:
Please see full Prescribing Information, including BOXED WARNING.
OK. We'll need you to sign in before we can determine if you are aligned with a sales representative.
If you select 'Yes', you will be required to enter your username and password in the sign-in form that will appear over this window.
Would you like to sign in now?